BioSpace News Archive

Auris Medical Announces Pricing of $5.5M Registered Direct Offering

The Company also agreed to issue warrants to purchase up to an aggregate of 7,499,999 common shares to the investors in a concurrent private placement.

January 30, 2018
·
4 min read
Deals

Eyenovia Announces Closing of $27.3M Initial Public Offering

Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services and Roth Capital Partners acted as joint book-running managers for the offering.

January 30, 2018
·
2 min read
Biotech Bay

Five Prime Therapeutics Announces Closing of Upsized Public Offering

Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Leerink Partners LLC are acting as book-running managers for the offering.

January 30, 2018
·
1 min read
Business

Amarin Announces Proposed Public Offering of American Depositary Shares

On January 26, 2018, the last sale price of the ADSs on The NASDAQ Global Market was $4.27 per share.

January 30, 2018
·
4 min read
Biotech Bay

Iovance Biotherapeutics Announces Closing of $172.5M Common Stock Public Offering

Iovance intends to use the proceeds from this offering to fund its ongoing clinical trials for its current product candidates, including its ongoing Phase 2 clinical trials of LN-144,

January 30, 2018
·
4 min read
Business

University of Iowa Health Care Increases Industry-Sponsored Clinical Trial Opportunities With TriNetX

In the first six months, UI Health Care was provided access to over 40 clinical trial opportunities from biopharmaceutical companies and CROs on the network.

January 30, 2018
·
3 min read
Business

GW Pharmaceuticals to Report Q1 Financial Results and Host Conference Call on 5 February, 2018

A replay of the call will also be available through the Company’s website (www.gwpharm.com) shortly after the call.

January 30, 2018
·
1 min read
Business

Dova Pharmaceuticals Announces the Appointment of Mark W. Hahn as CFO

Mark will officially commence in his role as Chief Financial Officer of Dova on January 31st, 2018.

January 30, 2018
·
3 min read
Drug Development

Corbus Pharma Announces Agreement With FDA on Phase IIb Cystic Fibrosis Study Design with Pulmonary Exacerbations as Sole Primary Endpoint

The Company and the FDA agreed that the event rate of pulmonary exacerbation is an acceptable sole primary efficacy endpoint for the clinical development program to support registration of lenabasum for the treatment of CF.

January 30, 2018
·
9 min read
Business

Vetter Initiates Reconstruction Activity at its Recently Purchased Des Plaines Site

Vetter announced today that initial reconstruction work on the 18 acres Des Plaines site purchased earlier this year is scheduled to begin this month.

January 30, 2018
·
2 min read